BACKGROUND Current surgical and medical treatment options for functional mitral regurgitation (FMR) are limited
the MV apparatus itself but on an indirect deficiency of MV function caused by ischemic or nonischemic dilated left heart disease (4).
This functional MR (FMR) is caused by left ventricular (LV) and/or MV annular dilation and papillary muscle displacement (4, 5) . The progression of LV dilation in such patients aggravates MV leaflet malcoaptation and thereby induces further LV dilation (6) (7) (8) .
FMR exacerbates heart failure-related symptoms, and increased hospitalization and mortality rates (9, 10) . Current medical treatment is limited, as it targets only heart failure symptoms and not the underlying cause of disease and-in contrast to DMR-the prognostic and clinical benefit of surgical treatment is controversial (3, 11) . PATIENT ENROLLMENT. Detailed patient inclusion and exclusion criteria are given in Online Table 2 . Table 1 shows eligibility criteria for study inclusion.
In brief, symptomatic patients with chronic FMR on stable guideline directed heart failure medication and/or device therapy were eligible for study inclusion when echocardiography confirmed FMR grade $2, and LV ejection fraction (LVEF) $20%.
Main exclusion criteria were interventional/surgical revascularization within 3 months before study inclusion, and contraindications for transfemoral interventional procedures such as LV thrombus or severe peripheral vascular disease.
All patients were under stable optimal medical therapy, which was determined by the investigator.
Compliance incidence was observed during the study for the following medications: angiotensinconverting enzyme inhibitor/angiotensin II blocker (baseline 95.8%), beta-blocker (baseline 97.2%), and diuretics (98.6%). Compliance was observed at baseline and all subsequent follow-up periods.
STUDY ENDPOINTS AND FOLLOW-UP PROCEDURES. Primary endpoints of this study were to assess safety and performance of the direct annuloplasty with the percutaneous annuloplasty system (Online Table 3 ).
Safety was defined as the 30-day composite of death, stroke, myocardial infarction, or emergent surgery or intervention.
Performance was defined with as need of MV-related cardiac surgery/intervention, device After femoral access, the 14-F deflectable guiding catheter is introduced into the left ventricle and directed towards the posterior annulus ( Figure 1A ). Table 2) .
THIRTY-DAY OUTCOMES OF PATIENTS WITH IMPLANTS.
There were no intraprocedural death and no necessity All-cause mortality through 30 days was 4.4%, 2 patients died of cardiogenic shock or decompensated heart failure at 14 and 18 days post-procedure (Table 3) . When separating patients with implants (n ¼ 45) from subjects without treatment (n ¼ 21), 30-day mortality rates were 4.4% in treated patients and 14.3% in untreated patients (p ¼ 0.2). Online Table 5 gives additional information on differences in clinical endpoints and LV remodeling in these patient groups during 30 days and 6 months of follow up.
SAFETY AND PERFORMANCE DATA AT 6 MONTHS AFTER TREATMENT WITH IMPLANTS. All-cause mortality was 12.2%, nonemergent MV surgery was performed in 1 patient (2.4%), and alternative catheter-based MV intervention with the MitraClip was performed in 7 patients (17.1%) within the 6-month follow-up ( Table 3) .
Five deaths were reported through the 6-month follow up. Only 2 of these deaths were considered related to either procedure or device and procedure.
Both of these deaths occurred at 14 and 18 days, Table 4) .
CHANGES IN MV GEOMETRY AND SEVERITY OF MR.
Analysis of core lab data showed significant changes in MV annular geometry with reduction of the anterior-posterior and septal-lateral dimensions of the mitral annulus. Concerning valve-specific echo data, coaptation length of the MV leaflets increased and tenting distance showed significant differences as compared to baseline data ( Table 5 ).
There was a trend toward a reduction in MR grade and semiquantitative variables on MR severity, which did not reach statistical significance ( 
DISCUSSION
In this study we were able to show that minimal invasive, percutaneous direct mitral annuloplasty is feasible with a dedicated annuloplasty system. Following this minimal invasive approach, procedural complication and 6-month mortality rates were low; thereby, the percutaneous annuloplasty system met its pre-specified endpoints on device safety and performance. The results of this feasibility study on a new interventional annuloplasty system must be interpreted in the light of the available evidence and treatment options for high-risk FMR patients. It cannot be excluded that in line with surgical annuloplasty recurrence of MR may occur over time 
